A detailed history of Susquehanna International Group, LLP transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 96,348 shares of ANIX stock, worth $335,291. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,348
Previous 112,393 14.28%
Holding current value
$335,291
Previous $248,000 22.18%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.21 - $3.48 $35,459 - $55,836
-16,045 Reduced 14.28%
96,348 $303,000
Q2 2024

Aug 15, 2024

SELL
$2.21 - $3.35 $505,113 - $765,669
-228,558 Reduced 67.04%
112,393 $248,000
Q1 2024

May 07, 2024

BUY
$3.08 - $5.02 $824,355 - $1.34 Million
267,648 Added 365.13%
340,951 $1.06 Million
Q4 2023

Feb 14, 2024

BUY
$2.85 - $4.19 $104,438 - $153,542
36,645 Added 99.96%
73,303 $284,000
Q3 2023

Nov 14, 2023

SELL
$2.97 - $3.87 $31,482 - $41,022
-10,600 Reduced 22.43%
36,658 $119,000
Q2 2023

Aug 11, 2023

SELL
$3.0 - $5.97 $325,578 - $647,900
-108,526 Reduced 69.66%
47,258 $151,000
Q1 2023

May 16, 2023

BUY
$3.86 - $5.0 $327,177 - $423,805
84,761 Added 119.34%
155,784 $669,000
Q4 2022

Feb 14, 2023

BUY
$3.78 - $5.81 $117,614 - $180,778
31,115 Added 77.97%
71,023 $301,000
Q3 2022

Nov 14, 2022

BUY
$2.81 - $6.15 $62,154 - $136,031
22,119 Added 124.34%
39,908 $196,000
Q2 2022

Aug 15, 2022

SELL
$2.55 - $4.1 $3,853 - $6,195
-1,511 Reduced 7.83%
17,789 $54,000
Q4 2021

Feb 14, 2022

SELL
$2.88 - $5.5 $76,625 - $146,333
-26,606 Reduced 57.96%
19,300 $57,000
Q3 2021

Nov 15, 2021

BUY
$3.57 - $5.6 $103,530 - $162,400
29,000 Added 171.54%
45,906 $219,000
Q2 2021

Aug 11, 2021

BUY
$3.46 - $4.92 $58,494 - $83,177
16,906 New
16,906 $66,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $107M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.